The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
Version 2 2024-06-13, 15:00
Version 1 2022-10-21, 02:01
journal contribution
posted on 2024-06-13, 15:00 authored by SJ Harrison, H Quach, E Link, H Feng, J Dean, M Copeman, H Van De Velde, A Schwarer, B Baker, A Spencer, J Catalano, P Campbell, B Augustson, K Romeril, HM PrinceThe addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit
History
Journal
American Journal of HematologyVolume
90Pagination
E86-E91Location
United StatesPublisher DOI
ISSN
0361-8609eISSN
1096-8652Language
enPublication classification
C1.1 Refereed article in a scholarly journalIssue
5Publisher
WileyUsage metrics
Keywords
AdultAgedAged, 80 and overAntineoplastic AgentsBoronic AcidsBortezomibDexamethasoneDrug Administration ScheduleDrug MonitoringDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMultiple MyelomaOdds RatioProspective StudiesPyrazinesRecurrenceRemission InductionSurvival AnalysisTime FactorsTreatment Outcome
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC